Valneva SE (NASDAQ:VALN) is one of the most undervalued biotech stocks to buy right now. Guggenheim cut the price target on Valneva SE (NASDAQ:VALN) to $11 from $13 on April 16, reiterating a Buy ...

Valneva shares hit €2.34 low as Goldman Sachs downgrades to Sell, citing failed Lyme trial and Chikungunya withdrawal, though Pfizer partnership and European sales offer hope.

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, ...

Valneva SE (NASDAQ: VALN) on Monday said it has decided to voluntarily withdraw the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, ...

In this article, we will look at the 8 Most Undervalued Biotech Stocks to Buy Right Now.

VIENNA, Austria, March 18, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive ...

Valneva (VALN) and the world’s largest vaccine maker, Serum Institute of India, announced on Wednesday that they have mutually agreed to discontinue their licensing agreement for the former’s ...

(RTTNews) - Valneva (VALN, VLA.PA, VLA.VI) Thursday reported an increase in preliminary full-year 2025 revenues, compared to the prior year. The vaccine company also provided an initial outlook for ...

FILE PHOTO: The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner/File Photo Jan 19 (Reuters) - French ...